The novel medication, retatrutide, is sparking significant excitement in the UK regarding a possible solution for obesity. Developed by the manufacturer, it integrates the actions of different glucagon-like peptide-1 (GLP-1) receptor agonists and a glucose-dependent insulinotropic polypeptide (GI